224 related articles for article (PubMed ID: 22871798)
1. Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer.
Zaczek AJ; Markiewicz A; Seroczynska B; Skokowski J; Jaskiewicz J; Pienkowski T; Olszewski WP; Szade J; Rhone P; Welnicka-Jaskiewicz M; Jassem J
Oncologist; 2012; 17(10):1246-55. PubMed ID: 22871798
[TBL] [Abstract][Full Text] [Related]
2. Copy number analysis of c-erb-B2 (HER-2/neu) and topoisomerase IIalpha genes in breast carcinoma by quantitative real-time polymerase chain reaction using hybridization probes and fluorescence in situ hybridization.
Murthy SK; Magliocco AM; Demetrick DJ
Arch Pathol Lab Med; 2005 Jan; 129(1):39-46. PubMed ID: 15628907
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
Fountzilas G; Dafni U; Bobos M; Kotoula V; Batistatou A; Xanthakis I; Papadimitriou C; Kostopoulos I; Koletsa T; Tsolaki E; Televantou D; Timotheadou E; Koutras A; Klouvas G; Samantas E; Pisanidis N; Karanikiotis C; Sfakianaki I; Pavlidis N; Gogas H; Linardou H; Kalogeras KT; Pectasides D; Dimopoulos MA
BMC Cancer; 2013 Mar; 13():163. PubMed ID: 23537287
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer.
Qiao JH; Jiao DC; Lu ZD; Yang S; Liu ZZ
Tumour Biol; 2015 Sep; 36(9):6833-8. PubMed ID: 25846735
[TBL] [Abstract][Full Text] [Related]
5. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.
Fountzilas G; Valavanis C; Kotoula V; Eleftheraki AG; Kalogeras KT; Tzaida O; Batistatou A; Kronenwett R; Wirtz RM; Bobos M; Timotheadou E; Soupos N; Pentheroudakis G; Gogas H; Vlachodimitropoulos D; Polychronidou G; Aravantinos G; Koutras A; Christodoulou C; Pectasides D; Arapantoni P
J Transl Med; 2012 Jan; 10():10. PubMed ID: 22240029
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.
Arriola E; Rodriguez-Pinilla SM; Lambros MB; Jones RL; James M; Savage K; Smith IE; Dowsett M; Reis-Filho JS
Breast Cancer Res Treat; 2007 Dec; 106(2):181-9. PubMed ID: 17260090
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer.
Zaczek A; Markiewicz A; Supernat A; Bednarz-Knoll N; Brandt B; Seroczyńska B; Skokowski J; Szade J; Czapiewski P; Biernat W; Wełnicka-Jaśkiewicz M; Jassem J
Pathol Oncol Res; 2012 Oct; 18(4):885-94. PubMed ID: 22426810
[TBL] [Abstract][Full Text] [Related]
8. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.
Tubbs R; Barlow WE; Budd GT; Swain E; Porter P; Gown A; Yeh IT; Sledge G; Shapiro C; Ingle J; Haskell C; Albain KS; Livingston R; Hayes DF
J Clin Oncol; 2009 Aug; 27(24):3881-6. PubMed ID: 19620488
[TBL] [Abstract][Full Text] [Related]
9. HER-2, TOP2A and chromosome 17 alterations in breast cancer.
Beser AR; Tuzlali S; Guzey D; Dolek Guler S; Hacihanefioglu S; Dalay N
Pathol Oncol Res; 2007; 13(3):180-5. PubMed ID: 17922046
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.
Romero A; Martín M; Cheang MC; López García-Asenjo JA; Oliva B; He X; de la Hoya M; García Sáenz JÁ; Arroyo Fernández M; Díaz Rubio E; Perou CM; Caldés Llopis T
Am J Pathol; 2011 Apr; 178(4):1453-60. PubMed ID: 21435434
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.
Fountzilas G; Christodoulou C; Bobos M; Kotoula V; Eleftheraki AG; Xanthakis I; Batistatou A; Pentheroudakis G; Xiros N; Papaspirou I; Koumarianou A; Papakostas P; Bafaloukos D; Skarlos DV; Kalogeras KT
J Transl Med; 2012 Oct; 10():212. PubMed ID: 23092535
[TBL] [Abstract][Full Text] [Related]
12. TOP2A amplification in the absence of that of HER-2/neu: toward individualization of chemotherapeutic practice in breast cancer.
Glynn RW; Mahon S; Curran C; Callagy G; Miller N; Kerin MJ
Oncologist; 2011; 16(7):949-55. PubMed ID: 21705665
[TBL] [Abstract][Full Text] [Related]
13. Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.
Kotoula V; Bobos M; Alexopoulou Z; Papadimitriou C; Papadopoulou K; Charalambous E; Tsolaki E; Xepapadakis G; Nicolaou I; Papaspirou I; Aravantinos G; Christodoulou C; Efstratiou I; Gogas H; Fountzilas G
PLoS One; 2014; 9(8):e103707. PubMed ID: 25098819
[TBL] [Abstract][Full Text] [Related]
14. Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer.
Mitrović O; Čokić V; Đikić D; Budeč M; Vignjević S; Subotički T; Gulan M; Radović S; Furtula S
Target Oncol; 2014 Dec; 9(4):367-79. PubMed ID: 24272208
[TBL] [Abstract][Full Text] [Related]
15. Aberrations of ERBB2 and TOP2A genes in breast cancer.
Nielsen KV; Müller S; Møller S; Schønau A; Balslev E; Knoop AS; Ejlertsen B
Mol Oncol; 2010 Apr; 4(2):161-8. PubMed ID: 19945923
[TBL] [Abstract][Full Text] [Related]
16. TOP2A gene copy number change in breast cancer.
Engstrøm MJ; Ytterhus B; Vatten LJ; Opdahl S; Bofin AM
J Clin Pathol; 2014 May; 67(5):420-5. PubMed ID: 24403186
[TBL] [Abstract][Full Text] [Related]
17. Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer.
Chen JR; Chien HP; Chen KS; Hwang CC; Chen HY; Yeh KY; Hsieh TY; Chang LC; Hsu YC; Lu RJ; Hua CC
Medicine (Baltimore); 2017 Jan; 96(2):e5582. PubMed ID: 28079792
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts.
Usha L; Tabesh B; Morrison LE; Rao RD; Jacobson K; Zhu A; Basu S; Coon JS
J Hematol Oncol; 2008 Aug; 1():12. PubMed ID: 18702822
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
O'Malley FP; Chia S; Tu D; Shepherd LE; Levine MN; Bramwell VH; Andrulis IL; Pritchard KI
J Natl Cancer Inst; 2009 May; 101(9):644-50. PubMed ID: 19401546
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer.
Wu Y; Han Y; Li Q; Zhang P; Yuan P; Luo Y; Fan Y; Chen S; Cai R; Li Q; Xu H; Wang Y; Ma F; Wang J; Xu B
Breast Cancer Res Treat; 2022 Jun; 193(2):381-392. PubMed ID: 35297009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
